Impact of hypertension on vascular remodeling in patients with psoriatic arthritis

[1]  H. Völzke,et al.  Psoriasis is associated with increased intima-media thickness--the Study of Health in Pomerania (SHIP). , 2012, Atherosclerosis.

[2]  Francesco Faita,et al.  Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study , 2012, Journal of hypertension.

[3]  S. Khosla,et al.  Emerging Role of Circulating Calcifying Cells in the Bone-Vascular Axis , 2012, Circulation.

[4]  L. Punzi,et al.  Atherosclerosis in psoriatic arthritis. , 2011, Autoimmunity reviews.

[5]  G. Di Minno,et al.  Carotid Intima-Media Thickness in Psoriatic Arthritis: Differences Between Tumor Necrosis Factor-&agr; Blockers and Traditional Disease-Modifying Antirheumatic Drugs , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[6]  C. Vrabie,et al.  Accelerated atherosclerosis in autoimmune rheumatic diseases , 2010 .

[7]  J. Hansen,et al.  Relation between serum osteoprotegerin and carotid intima media thickness in a general population – the Tromsø Study , 2010, Journal of thrombosis and haemostasis : JTH.

[8]  Vinod Chandran,et al.  Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. , 2010, Rheumatology.

[9]  M. Bäck,et al.  Leukotrienes and atherosclerosis. , 2010, Current drug targets.

[10]  A. Nordström,et al.  Osteoprotegerin Promotes Fibrous Cap Formation in Atherosclerotic Lesions of ApoE-Deficient Mice—Brief Report , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[11]  L. Ghiadoni,et al.  Endothelium‐dependent contractions and endothelial dysfunction in human hypertension , 2009, British journal of pharmacology.

[12]  K. Dellsperger,et al.  Role of TNF-α in vascular dysfunction , 2009, Clinical science.

[13]  P. D’Amelio,et al.  The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. , 2009, Journal of endocrinological investigation.

[14]  H. Bitterman,et al.  Subclinical atherosclerosis in psoriatic arthritis: a case-control study. , 2008, The Journal of rheumatology.

[15]  P. Palatini,et al.  Increase in Carotid Intima-Media Thickness in Grade I Hypertensive Subjects: White-Coat Versus Sustained Hypertension , 2008, Hypertension.

[16]  T. Pincus,et al.  Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. , 2007, Atherosclerosis.

[17]  A. Dominiczak,et al.  2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.

[18]  Javier Martín,et al.  High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. , 2007, Arthritis and rheumatism.

[19]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[20]  Javier Martín,et al.  Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. , 2007, Arthritis and rheumatism.

[21]  T. Rabelink,et al.  Endothelial function and dysfunction: testing and clinical relevance. , 2007, Circulation.

[22]  Marcello Demi,et al.  A System for Real-Time Measurement of the Brachial Artery Diameter in B-Mode Ultrasound Images , 2007, IEEE Transactions on Medical Imaging.

[23]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[24]  L. Naldi,et al.  Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. , 2006, Clinical and experimental rheumatology.

[25]  A. Zannettino,et al.  Osteoprotegerin (OPG) is localized to the Weibel‐Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor , 2005, Journal of cellular physiology.

[26]  Ildikó Kriszbacher,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, New England Journal of Medicine.

[27]  Y. Shoenfeld,et al.  Inflammation and accelerated atherosclerosis: basic mechanisms. , 2005, Rheumatic diseases clinics of North America.

[28]  D. Gladman,et al.  Psoriatic arthritis assessment tools in clinical trials , 2005, Annals of the rheumatic diseases.

[29]  Gian Paolo Rossi,et al.  Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. , 2005, Journal of hypertension.

[30]  E. Vicaut,et al.  Mannheim Intima-Media Thickness Consensus , 2004, Cerebrovascular Diseases.

[31]  M. Paterni,et al.  In vivo noninvasive identification of cell composition of intimal lesions: a combined approach with ultrasonography and immunocytochemistry. , 2003, Journal of vascular surgery.

[32]  A. Hamsten,et al.  Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. , 2002, European heart journal.

[33]  M. Pfeffer,et al.  Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. , 2000, Circulation.

[34]  E. Casiglia,et al.  Factors underlying the increase in carotid intima-media thickness in borderline hypertensives. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  L. Iversen,et al.  Significance of leukotriene-A4 hydrolase in the pathogenesis of psoriasis. , 1997, Skin pharmacology : the official journal of the Skin Pharmacology Society.